Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents

Diabetes, Obesity and Metabolism

Volumn 14, Issue 7, 2012, Pages 608-615

  Roth, J D ^a   D'Souza, L ^a   Griffin, P S ^a   Athanacio, J ^a   Trevaskis, J L ^a   Nazarbaghi, R ^a   Jodka, C ^a   Hoyt, J ^a   Forood, B ^a   Parkes, D G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Body weight obesity; Combination; Food intake; Melanocortins

Indexed keywords

AMIDE; AMYLIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN RECEPTOR AGONIST; RECOMBINANT LEPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FOOD INTAKE; KNOCKOUT MOUSE; MALE; MONOTHERAPY; NONHUMAN; OBESITY; RAT; WEIGHT CONTROL; WILD TYPE;

EID: 84861882178     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01570.x     Document Type: Article

References (40)

1. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31: 1816-1823.
2. Smith SR, Blundell JE, Burns C et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007; 293: E620-E627.
3. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006; 147: 5855-5864.
4. Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008; 105: 7257-7262.
5. Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity 2010; 18: 21-26.
6. Turek VF, Trevaskis JL, Levin BE et al. Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 2010; 151: 143-152.
7. Huszar D, Lynch CA, Fairchild-Huntress V et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
8. Raposinho PD, Castillo E, d'Alleves V, Broqua P, Pralong FP, Aubert ML. Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes. Endocrinology 2000; 141: 4419-4427.
9. Farooqi IS, Yeo GS, Keogh JM et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106: 271-279.
10. Nargund RP, Strack AM, Fong TM. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J Med Chem 2006; 49: 4035-4043.
11. He S, Ye Z, Dobbelaar PH et al. Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett 2010; 20: 2106-2110.
12. Mul JD, van Boxtel R, Bergen DJ et al. Melanocortin receptor 4 deficiency affects body weight regulation, grooming behavior, and substrate preference in the rat. Obesity 2011; doi:10.1038/oby.2011.81
13. Hsiung HM, Hertel J, Zhang XY et al. A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats. Endocrinology 2005; 146: 5257-5266.
14. Trevaskis JL, Coffey T, Cole R et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008; 149: 5679-5687.
15. Roth JD, Coffey T, Jodka CM et al. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 2007; 148: 6054-6061.
16. Roth JD, Trevaskis JL, Wilson J et al. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Int J Obes 2008; 32: 1201-1210.
17. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Anti-obesity effects of the β-cell hormone amylin in diet induced obese rats: effects on food intake, body weight, composition, energy expenditure and gene expression. Endocrinology 2006; 147: 5855-5864.
18. Lutz TA, Geary N, Szabady MM, Del Prete E, Scharrer E. Amylin decreases meal size in rats. Physiol Behav 1995; 58: 1197-1202.
19. Eiden S, Daniel C, Steinbrueck A, Schmidt I, Simon E. Salmon calcitonin - a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. J Physiol 2002; 541: 1041-1048.
20. Barth SW, Riediger T, Lutz TA, Rechkemmer G. Differential effects of amylin and salmon calcitonin on neuropeptide gene expression in the lateral hypothalamic area and the arcuate nucleus of the rat. Neurosci Lett 2003; 341: 131-134.
21. Osto M, Wielinga PY, Alder B, Walser N, Lutz TA. Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin. Physiol Behav 2007; 91: 566-572.
22. Seth R, Knight WD, Overton JM. Combined amylin-leptin treatment lowers blood pressure and adiposity in lean and obese rats. Int J Obes 2011; 35: 1183-1192.
23. Trevaskis JL, Parkes DG, Roth JD. Insights into amylin-leptin synergy. Trends Endocrinol Metab 2010; 21: 473-479.
24. Irani BG, Xiang Z, Yarandi HN et al. Implication of the melanocortin-3 receptor in the regulation of food intake. Eur J Pharmacol 2011; 660: 80-87.
25. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity 2010; 18: 1739-1746.
26. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 1998; 64: 557-561.
27. Trevaskis JL, Turek VF, Griffin PS, Wittmer C, Parkes DG, Roth JD. Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin? Physiol Behav 2010; 100: 187-195.
28. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5: 1066-1070.
29. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 2002; 51: 1337-1345.
30. Tian X, Switzer AG, Derose SA et al. Discovery of orally bioavailable 1, 3, 4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents. J Med Chem 2008; 51: 6055-6066.
31. Krishna R, Gumbiner B, Stevens C et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009; 86: 659-666.
32. Greenfield JR. Melanocortin signalling and the regulation of blood pressure in human obesity. J Neuroendocrinol 2011; 23: 186-193.
33. Bluher S, Ziotopoulou M, Bullen JW Jr et al. Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes 2004; 53: 82-90.
34. Roth JD, Trevaskis JL, Turek VF, Parkes DG. "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations. Brain Res 2010; 1350: 86-94.
35. Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 2010; 100: 511-518.
36. Rowland NE, Schaub JW, Robertson KL, Andreasen A, Haskell-Luevano C. Effect of MTII on food intake and brain c-Fos in melanocortin-3, melanocortin-4, and double MC3 and MC4 receptor knockout mice. Peptides 2010; 31: 2314-2317.
37. Trivedi P, Jiang M, Tamvakopoulos CC et al. Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Res 2003; 977: 221-230.
38. Grill HJ, Ginsberg AB, Seeley RJ, Kaplan JM. Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J Neurosci 1998; 18: 10128-10135.
39. Bronstein DM, Schafer MK, Watson SJ, Akil H. Evidence that beta-endorphin is synthesized in cells in the nucleus tractus solitarius: detection of POMC mRNA. Brain Res 1992; 587: 269-275.
40. Ellacott KL, Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res 2004; 59: 395-408.